Salix Pharmaceuticals Completes Acquisition of Santarus

13-01-2014 Business Wire HealthComments (0)

PharmaceuticalSalix Pharmaceuticals

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., (NASDAQ:SNTS), at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any r

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top